Zealand Pharma Loses Fifth of Value After Trial Dropouts
Danish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Learn when mutual funds can be preferable to index funds, considering objectives, risk tolerance, and horizon. Make informed allocation decisions.
25,127 articlesDanish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
A fresh Wall Street call boosts Broadcom stock, signaling a potential historic buy as AI chip demand and a multi-year...
As AI workloads push memory demand higher, micron stock could have substantial upside. Yet a high-capex Virginia expa...
Bitcoin, Ethereum, and XRP flashed potential buy signals after a wide market drop, according to on-chain analytics. A...
May brought a sharp rally for Tower Semiconductor as demand surged and orders extended into 2028. This analysis break...
Adobe is expected to announce its next chief executive on Thursday, with the board leaning toward an internal candida...
A wave of token launches has stumbled, pushing traders toward tokenized stocks. Exchanges are racing to monetize reta...
Amazon expands its AI funding spree, locking in another $17.5 billion in external financing as total external funding...
Insider moves often spark questions when a stock rallies. This article examines Nayax's CMO sale during a solid run, ...
As lawmakers grapple with federal spending, fresh numbers show social security benefits costs are manageable today, a...
Adobe prepares to report Q2 results after the bell as investors scrutinize AI-driven growth, ARR expansion, and capit...
JPMorgan argues investors are underestimating the upside from SpaceX mega IPOs and other blockbuster listings, sugges...